679 related articles for article (PubMed ID: 29478344)
21. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials.
Howell ST; Cardwell LA; Feldman SR
Ann Pharmacother; 2018 Apr; 52(4):380-387. PubMed ID: 29134822
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Gordon KB; Blauvelt A; Foley P; Song M; Wasfi Y; Randazzo B; Shen YK; You Y; Griffiths CEM
Br J Dermatol; 2018 Jan; 178(1):132-139. PubMed ID: 28940259
[TBL] [Abstract][Full Text] [Related]
23. Anti-IL-23 Phase II Data for Psoriasis: A Review.
Beroukhim K; Danesh MJ; Nguyen C; Austin A; Koo J; Levin E
J Drugs Dermatol; 2015 Oct; 14(10):1093-6. PubMed ID: 26461819
[TBL] [Abstract][Full Text] [Related]
24. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis.
Vu TT; Gooderham M; Papp K
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1423-1433. PubMed ID: 27690669
[TBL] [Abstract][Full Text] [Related]
25. Review of phase III trial data on IL-23 inhibitors tildrakizumab and guselkumab for psoriasis.
Amin M; Darji K; No DJ; Wu JJ
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1627-1632. PubMed ID: 28667777
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
27. IL-23 inhibitors for moderate-to-severe psoriasis.
Ibler E; Gordon KB
Semin Cutan Med Surg; 2018 Sep; 37(3):158-162. PubMed ID: 30215632
[TBL] [Abstract][Full Text] [Related]
28. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
29. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
[TBL] [Abstract][Full Text] [Related]
30. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Boehncke WH; Brembilla NC; Nissen MJ
Expert Rev Clin Immunol; 2021 Jan; 17(1):5-13. PubMed ID: 33251833
[TBL] [Abstract][Full Text] [Related]
31. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
32. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
[No Abstract] [Full Text] [Related]
33. Risankizumab (Skyrizi) for psoriasis.
Med Lett Drugs Ther; 2019 Jun; 61(1573):81-83. PubMed ID: 31170118
[No Abstract] [Full Text] [Related]
34. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
Tausend W; Downing C; Tyring S
J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
[TBL] [Abstract][Full Text] [Related]
35. Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis.
Wong IT; Shojania K; Dutz J; Tsao NW
Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):153-66. PubMed ID: 26681527
[TBL] [Abstract][Full Text] [Related]
36. Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
Chiricozzi A; Costanzo A; Fargnoli MC; Malagoli P; Piaserico S; Amerio P; Argenziano G; Balato N; Bardazzi F; Bianchi L; Carrera CG; Conti A; Dapavo P; De Simone C; Loconsole F; Lo Schiavo A; Malara G; Musumeci ML; Parodi A; Peris K; Prignano F; Rongioletti F; Talamonti M; Potenza C
Eur J Dermatol; 2021 Feb; 31(1):3-16. PubMed ID: 33648915
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
[TBL] [Abstract][Full Text] [Related]
38. Guselkumab for the treatment of psoriasis.
Megna M; Balato A; Raimondo A; Balato N
Expert Opin Biol Ther; 2018 Apr; 18(4):459-468. PubMed ID: 29482382
[TBL] [Abstract][Full Text] [Related]
39. Safety of secukinumab in the treatment of psoriasis.
Blauvelt A
Expert Opin Drug Saf; 2016 Oct; 15(10):1413-20. PubMed ID: 27545070
[TBL] [Abstract][Full Text] [Related]
40. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.
Egeberg A; Andersen YMF; Halling-Overgaard AS; Alignahi F; Thyssen JP; Burge R; Mallbris L
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):39-46. PubMed ID: 31465593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]